FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	9	,					

ı	OMB APPRO	JVAL
	OMB Number:	3235-0287
	Estimated average bur	den
	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or Section 30(n) or the investment Company Act or 1940	
1. Name and Addres Kreis Leslie V (Last)	ss of Reporting Perso W.	on* (Middle)	2. Issuer Name and Ticker or Trading Symbol COGNITION THERAPEUTICS INC [CGTX]	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)
C/O BIOS EQUITY PARTNERS 1751 RIVER RUN, SUITE 400		(madio)	3. Date of Earliest Transaction (Month/Day/Year) 11/16/2022	
(Street) FORT WORTH (City)	TX (State)	76107 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2A. Deemed Execution Date, 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership Form: Direct (D) or Indirect 1. Title of Security (Instr. 3) 2. Transaction 5. Amount of 7. Nature of Date (Month/Day/Year) Securities Beneficially Indirect Beneficial Transaction if any Code (Instr. 8) Owned Following Reported Ownership (Instr. 4) (Month/Day/Year) (I) (Instr. 4) (A) or (D) Transaction(s) (Instr. 3 and 4) ٧ Price Code Amount By Bios Fund III 11/16/2022 \$1.4(5) Common Stock P 8,722 324,760 I A NT, LP(1) (2)(3)(4) By Bios Fund III **\$1.4**⁽⁵⁾ 11/16/2022 54,009 2,009,686 I Common Stock **QP**, L**P**⁽¹⁾ (2)(3)(4) **Bios Fund** 11/16/2022 8,269 **\$1.4**⁽⁵⁾ Common Stock 307,877 III, $LP^{(1)(2)}$ (3)(4) By Bios Memory Common Stock I 1,424,014 SPV I, LP(1)(2)(3)(4) By: Bios Common Stock 418,926 I Fund I, LP(1)(2)(3)(4) By: Bios Fund I Common Stock 245,029 Ι **QP**, L**P**⁽¹⁾ (2)(3)(4) By: Bios 78,298 Common Stock Ι Fund II, LP(1)(2)(3)(4) By: Bios Fund II Common Stock 255,765 I **QP**, LP⁽¹⁾ (2)(3)(4) By: Bios Fund II Common Stock 34,238 NT, LP(1) (2)(3)(4) By Bios Memory Common Stock 385,248 I SPV II, $\mathbf{LP}^{(1)(2)(3)(4)}$

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Tal Date (Month/Day/Year)	Pepperivat Execution Date, if any (e.g., pu	VeSe Transa ItSo,d€€	CUI Iction	ritiēs ^{Ny} , w as ni	Archqiu Zants,	ife chte Trys f Expiration Da Opplions y/	ioseddaof, o ate convertib	16 e 6	QUEITIES) Security	9. Number of derivative Securities	10. Ownership Form:
(Instr. 3)	Price of Derivative Security		-(Month/Ďay/Yéar)	8)		Acqu (A) o Disp	rities uired r osed) r. 3, 4		,	Unde Deriv	rlying ative rity (Instr.	(Instr. 5)	Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (Sode		n of Deriv SANcu	mber ative	6. Date Exerc Expiration Da Patenth/Day/\ Exercisable	ate	Amou Secu Uille e	lyshagres	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially	10. Ownership Form: Direct (D)
	Berivative of Address of eslie W.	Reporting Person*				of (D	r osed) r. 3, 4			Deriv Secu 3 and	rity (Instr.		Owned Following Reported Transaction(s) (Instr. 4)	or indirect (I) (Instr. 4)
1		First) PARTNERS SUITE 400	(Middle)	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
(Street)	ORTH	TX	76107											
(City)		(State)	(Zip)		-									
	d Address of	Reporting Person*												
(Last) 1751 RIV		(First) SUITE 400	(Middle)											
(Street)	ORTH	TX	76107											
(City)		(State)	(Zip)											
	d Address of	Reporting Person*												
(Last) 1751 RIV		(First) SUITE 400	(Middle)											
(Street) FORT W	ORTH	TX	76107		-									
(City)		(State)	(Zip)											
	d Address of Sund II N	Reporting Person* $\frac{T, LP}{}$												
(Last) 1751 RIV		(First) SUITE 400	(Middle)											
(Street)	ORTH	TX	76107											
(City)		(State)	(Zip)		-									
		Reporting Person*												
(Last) 1751 RIV		(First) SUITE 400	(Middle)		-									
(Street)					-									

FORT WORTH

(City)

(Last)

TX

(State)

(First)

1. Name and Address of Reporting Person*
BIOS Equity Partners III, LP

76107

(Zip)

(Middle)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

1751 RIVER RUN	I, SUITE 400								
(Street) FORT WORTH	TX	76107							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person* BIOS Fund III, LP									
(Last) 1751 RIVER RUN	(First) J, SUITE 400	(Middle)							
(Street) FORT WORTH	TX	76107							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person* BIOS Fund III QP, LP									
(Last) 1751 RIVER RUN	(First) I, SUITE 400	(Middle)							
(Street) FORT WORTH	TX	76107							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person* BIOS Fund III NT, LP									
(Last) 1751 RIVER RUN	(First) I, SUITE 400	(Middle)							
(Street) FORT WORTH	TX	76107							
(City)	(State)	(Zip)							

Explanation of Responses:

- 1. Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and Bios Memory SPV I, LP ("Bios Memory I"). Bios Equity Partners II, LP ("Bios Fund II QP, LP ("Bios Fund II QP, LP ("Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Memory SPV II, LP ("Bios Memory II"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund II QP, LP ("Bios Fund III QP"), Bios Fund III, LP ("Bios Fund III QP, LP ("Bios Fund III QP"), and Bios Fund III NT, LP ("Bios Fund III NT"), Bios Capital Management, LP ("Bios Management, LP ("Cavu Management,") are the general partners Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management.
- 2. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.
- 3. Mr. Kries, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
- 4. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.23 to \$1.54, inclusive. The reporting persons undertake to provide to Cognition Therapeutics Inc., any security holder of Cognition Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

Remarks

This Form 4 is the second of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The first Form 4 was filed by Aaron G.L. Fletcher as the designated filer.

/s/ Leslie W. Kreis, Jr.	11/17/2022
Cavu Advisors, LLC By: /s/ Leslie W. Kreis, Jr., Manager	11/17/2022
Cavu Management, LP By: Cavu Advisors, LLC, its general partner By: /s/ Leslie W. Kreis, Jr., Manager	11/17/2022
Bios Fund II NT, LP By: Bios Equity Partners II, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ Leslie W. Kreis, Jr., Manager	11/17/2022
Bios Memory SPV II, LP By:	11/17/2022

Bios Equity Partners, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ <u>Leslie W. Kreis, Jr.,</u> Manager Bios Equity Partners III, LP By: Cavu Management, LP, its general partner By: Cavu 11/17/2022 Advisors, LLC, its general partner By: /s/ Leslie W. Kreis, Jr., Manager Bios Fund III, LP By: Bios Equity Partners III, LP, its general partner By: Cavu Management, LP, its general 11/17/2022 partner By: Cavu Advisors, LLC, its general partner By: /s/ Leslie W. Kreis, Jr., Manager Bios Fund III QP, LP By: Bios Equity Partners III, LP, its general partner By: Cavu Management, LP, its general 11/17/2022 partner By: Cavu Advisors, LLC, its general partner By: /s/ Leslie W. Kreis, Jr., Manager Bios Fund III NT, LP By: Bios Equity Partners III, LP, its general partner By: Cavu Management, LP, its general 11/17/2022 partner By: Cavu Advisors,

Manager

** Signature of Reporting Person Date

LLC, its general partner By: /s/ Leslie W. Kreis, Jr.,

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).